Thank you, Shoa! It’s been a great pleasure working with you on various projects. I look forward to our continued collaboration!

Thank you, @sophie-gunn32.bsky.social!
Looking forward to working together again!

Thanks! @jamespirruccello.com!
Looking forward to working with you!

We’re building a team that values rigor and openness in science. If you’re interested in collaborating or working with us, please reach out to me via DM on X, Bluesky, or LinkedIn!

I’m deeply grateful to my postdoc mentors,
@pnatarajanmd.bsky.social and Dr. Patrick Ellinor. Your unwavering support and belief on me made this a reality. Also, thank you so much for all the colleagues and friends helped this process!

We’re also bringing genetics into clinical care. MGB Personalized Medicine now provides clinical polygenic risk score (PRS) testing using cutting-edge genotyping and PRS calibration workflows. This service is now available to institutions across the U.S.
massgeneralbrigham.org/en/research-...

If you’re interested in this topic and attending #ASHG2025
@geneticssociety.bsky.social in Boston, we’d love to see you at our talk!
📅 Sat, Oct 18, 9:15–9:30 AM ET
📍 Room 253ABC (Level 2)

As one example, we’re currently participating in a mega-scale genetic analysis of coronary artery disease involving ~4 million individuals, in collaboration with the CARDIoGRAMplusC4D consortium (cardiogramplusc4d.org) — a truly global effort.

Thanks to sustained investments in science, now we can access the data from millions of people to address a wide range of medical questions. We use large-scale genetic and clinical data to reveal disease biology and translate insights into better patient care.

I proudly advocate for 2002 as the year GWAS began 🙂
www.nature.com/articles/ng1...

Many thanks to the team and the participants in
@ukbiobank.bsky.social for making this study possible.

@somijemmacho.bsky.social, Sara Haidermota, Whitney Hornsby, Patrick Ellinor, and @pnatarajanmd.bsky.social!

10/ In summary:
Genetic predisposition to higher LDL-C → Lower T2D risk
No strong pathway-specific effects detected
Future research should refine mechanisms & mitigate risks

We are excited to contribute to this evolving discussion and look forward to future studies!

9/ What’s next?
This study raises important questions about the mechanisms linking LDL-C and T2D. Further research is needed to:
🔍 Identify the specific pathways involved in this relationship
⚕️ Develop strategies to mitigate the risk.

8/ Does this mean we should stop statins to prevent T2D?
🚫 Absolutely not.
Statins have clear cardiovascular benefits, and all randomized controlled trials consistently support their overall positive impact on health.

7/ What does this mean?
A wide range of genetic predictions for LDL-C levels were significantly negatively associated with future T2D risk. These effects were not confined to specific pathways, which may imply a broader and more direct role of LDL-C in T2D susceptibility.